# A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

Study · id `cardio:ct-nct07357675` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07357675](<https://clinicaltrials.gov/study/NCT07357675>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07357675

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07357675. Randomized; triple masking; primary purpose treatment. Start 2026-10-29 (actual); primary completion 2027-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07357675, source copy `cardio:ctgov-nct07357675-2026-11-02`, retrieved 2026-11-18)
- Started: 2026-10-29 (actual) (ClinicalTrials.gov record NCT07357675, source copy `cardio:ctgov-nct07357675-2026-11-02`, retrieved 2026-11-18)
- Primary completion: 2027-10-01 (anticipated) (ClinicalTrials.gov record NCT07357675, source copy `cardio:ctgov-nct07357675-2026-11-02`, retrieved 2026-11-18)
- Completion: 2027-12-01 (anticipated) (ClinicalTrials.gov record NCT07357675, source copy `cardio:ctgov-nct07357675-2026-11-02`, retrieved 2026-11-18)
- Countries: United States; Belgium; Netherlands; United Kingdom (ClinicalTrials.gov record NCT07357675, source copy `cardio:ctgov-nct07357675-2026-11-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07357675-2026-11-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
- Acronym: EasyBoost
- Condition: Coronary Artery Disease (CAD)
- Condition: Coronary Artery Bypass Graft Surgery(CABG)
- Intervention (Drug): EA-230 90mg/kg/hour
- Intervention (Drug): Placebo
- Lead sponsor: EBI Anti Sepsis BV
- Lead sponsor class: INDUSTRY
- Collaborator: CR2O B.V.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: 2791a207eda0ca40f1b106d525fd6c9756deb9315a1dc7f4b13de8eda68ec60c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
